503b bulk list
The Biggest Lie About Semaglutide 30% Cost Increase
A 15% price jump in semaglutide’s wholesale acquisition cost is often reported as a 30% increase, but the underlying driver is the FDA’s proposal to remove the drug from the 503B bulk list. The change reshapes how independent pharmacies obtain the medication and ripples through patient affordability. Medical